Santhera Pharmaceuticals Holding AG Total Assets
Santhera Pharmaceuticals Holding AG total assets. Based on the latest financial reports, Santhera Pharmaceuticals Holding AG (SANN) holds total assets worth CHF148.09 Million CHF (≈ $187.22 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see SANN company net worth for the company's overall valuation and market capitalisation.
Total Assets of Santhera Pharmaceuticals Holding AG (2006–2025)
Total assets of Santhera Pharmaceuticals Holding AG from 2006 to 2025. This chart illustrates how Santhera Pharmaceuticals Holding AG's total assets have evolved over time, based on quarterly financial data. See SANN share price today for real-time trading data and today's change.
Santhera Pharmaceuticals Holding AG - Asset Composition Analysis
Santhera Pharmaceuticals Holding AG Total Assets Breakdown (December 2025)
Santhera Pharmaceuticals Holding AG total assets breakdown as of December 2025. Santhera Pharmaceuticals Holding AG's total assets of CHF148.09 Million consist of 54.2% current assets and 45.8% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 15.2% |
| Accounts Receivable | CHF26.04 Million | 17.6% |
| Inventory | CHF24.87 Million | 16.8% |
| Property, Plant & Equipment | CHF0.00 | 0.0% |
| Intangible Assets | CHF63.94 Million | 43.2% |
| Goodwill | CHF0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Santhera Pharmaceuticals Holding AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Santhera Pharmaceuticals Holding AG short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Santhera Pharmaceuticals Holding AG's current assets represent 54.2% of total assets in 2025, a decrease from 78.9% in 2006.
- Cash Position: Cash and equivalents constituted 15.2% of total assets in 2025, down from 77.4% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 43.0% of total assets, an increase from 19.0% in 2006.
- Asset Diversification: The largest asset category is intangible assets at 43.2% of total assets.
Santhera Pharmaceuticals Holding AG Competitors by Total Assets
Key competitors of Santhera Pharmaceuticals Holding AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Santhera Pharmaceuticals Holding AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.29 | 1.64 | 0.61 |
| Quick Ratio | 0.89 | 1.26 | 0.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CHF18.07 Million | CHF29.67 Million | CHF-11.35 Million |
Santhera Pharmaceuticals Holding AG - Advanced Valuation Insights
This section examines the relationship between Santhera Pharmaceuticals Holding AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.48 |
| Latest Market Cap to Assets Ratio | 1.64 |
| Asset Growth Rate (YoY) | -2.9% |
| Total Assets | CHF148.09 Million |
| Market Capitalization | $243.45 Million USD |
Valuation Analysis
Above Book Valuation: The market values Santhera Pharmaceuticals Holding AG's assets above their book value (1.64x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: Santhera Pharmaceuticals Holding AG's assets decreased by 2.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Santhera Pharmaceuticals Holding AG (2006–2025)
The table below shows the annual total assets of Santhera Pharmaceuticals Holding AG from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CHF148.09 Million ≈ $187.22 Million |
-2.89% |
| 2024-12-31 | CHF152.49 Million ≈ $192.79 Million |
+39.09% |
| 2023-12-31 | CHF109.63 Million ≈ $138.60 Million |
+72.03% |
| 2022-12-31 | CHF63.73 Million ≈ $80.57 Million |
-30.06% |
| 2021-12-31 | CHF91.12 Million ≈ $115.20 Million |
+2.74% |
| 2020-12-31 | CHF88.69 Million ≈ $112.12 Million |
-22.92% |
| 2019-12-31 | CHF115.05 Million ≈ $145.46 Million |
+4.31% |
| 2018-12-31 | CHF110.29 Million ≈ $139.44 Million |
+0.47% |
| 2017-12-31 | CHF109.78 Million ≈ $138.79 Million |
+20.91% |
| 2016-12-31 | CHF90.79 Million ≈ $114.79 Million |
-22.50% |
| 2015-12-31 | CHF117.15 Million ≈ $148.11 Million |
+410.58% |
| 2014-12-31 | CHF22.95 Million ≈ $29.01 Million |
+135.67% |
| 2013-12-31 | CHF9.74 Million ≈ $12.31 Million |
-46.75% |
| 2012-12-31 | CHF18.29 Million ≈ $23.12 Million |
-64.86% |
| 2011-12-31 | CHF52.03 Million ≈ $65.79 Million |
-33.94% |
| 2010-12-31 | CHF78.77 Million ≈ $99.58 Million |
-16.83% |
| 2009-12-31 | CHF94.70 Million ≈ $119.73 Million |
-16.15% |
| 2008-12-31 | CHF112.95 Million ≈ $142.80 Million |
-21.66% |
| 2007-12-31 | CHF144.18 Million ≈ $182.28 Million |
-11.22% |
| 2006-12-31 | CHF162.39 Million ≈ $205.31 Million |
-- |
About Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pi… Read more